#1 Clinical Trials Search in Europe

ANX007

Clinical trials are investigating ANX007 in people with dry age-related macular degeneration with geographic atrophy. These studies are designed to evaluate safety and efficacy, especially effects on visual function and visual acuity. The main trial listed here is a Phase 3 study in 630 participants.

Table of Contents

Trial overview

The listed clinical trial is studying ANX007 in people with dry age-related macular degeneration (AMD) with geographic atrophy (GA).[1] This is an interventional study, which means researchers are giving a treatment and then measuring the results.[1] The trial is authorised and is designed to evaluate both efficacy and safety.[1]

Who the study is for

This study is for participants with dry AMD and GA.[1] These are eye conditions that can damage the macula, the part of the eye needed for sharp central vision.[1] The trial title also shows that the treatment is given by intravitreal injection, which means an injection into the eye.[1]

The source data do not list the full entry rules, so the exact participation criteria are not available here.[1] In clinical trials, people must meet the study rules before joining.[1]

What the study measures

The main outcome is confirmed best corrected visual acuity (BCVA) loss of 15 letters or more from baseline through Month 15.[1] BCVA is a standard eye test that checks the best vision a person can achieve with glasses or contact lenses if needed.[1] The ETDRS method is the letter-chart system used to measure this outcome.[1]

In simple terms, the study is asking whether vision stays more stable over time after treatment with ANX007.[1] The brief summary also says the study is evaluating effects on visual function and visual acuity.[1]

Study phase and size

This is a Phase 3 trial.[1] Phase 3 studies are usually larger than earlier studies and are used to look more closely at how well a treatment works and how safe it is in a bigger group of people.[1]

The planned enrollment is 630 participants.[1] A larger study size can help researchers better understand the trial results and how consistent they are across participants.[1]

What participation means

People in this trial receive ANX007 as an intravitreal treatment, meaning it is delivered into the eye.[1] The study then follows participants over time and checks vision-related outcomes, especially changes in BCVA through Month 15.[1]

Because only the trial record is available here, details such as visit schedule, extra tests, and the full list of eligibility rules are not provided.[1] The available data do show that the study is focused on a specific eye disease group and is measuring whether vision loss can be limited.[1]

Trial ID Phase Condition studied Status Enrollment
NCT06510816 Phase 3 Dry age-related macular degeneration with geographic atrophy Authorised 630

FAQ

  • What is ANX007 being studied for in these trials? ANX007 is being studied in people with dry age-related macular degeneration with geographic atrophy. The trial is focused on whether it can help protect vision and measure safety.
  • Who can take part in the ANX007 trial? The trial is for participants with dry age-related macular degeneration with geographic atrophy. People must meet the study’s specific entry rules to join.
  • What phase is the ANX007 trial? The listed study is a Phase 3 trial. Phase 3 trials are larger studies that look closely at how well a treatment works and how safe it is.
  • What is the main result being measured? The main result is confirmed best corrected visual acuity loss of 15 letters or more from the start of the study through Month 15. This means the study checks whether vision gets worse by a set amount.
  • How many people are planned for the study? The trial plans to enroll 630 participants. This larger number helps researchers better assess the study results.

Ongoing Clinical Trials on ANX007

  • Study on the Effectiveness and Safety of ANX007 Injections for Patients with Geographic Atrophy from Age-Related Macular Degeneration

    Not recruiting

    3 1 1
    Investigated drugs:
    Austria Czechia France Germany Hungary Italy +3

Glossary

  • Age-related macular degeneration (AMD): An eye disease that affects the macula, the part of the retina needed for sharp central vision.
  • Dry AMD: A common form of AMD that is not the wet type. It can slowly damage central vision.
  • Geographic atrophy (GA): A later stage of dry AMD where areas of the retina waste away, which can lead to vision loss.
  • Intravitreal injection: An injection given into the eye. In this trial, ANX007 is given this way.
  • Phase 3: A late-stage clinical trial that tests how well a treatment works and continues to monitor safety in a larger group.
  • Interventional study: A study where participants receive a treatment or procedure so researchers can measure its effects.
  • Efficacy: How well a treatment works in a study.
  • Safety: How well a treatment is tolerated and whether it causes unwanted effects.
  • Best corrected visual acuity (BCVA): A standard eye test that checks the best vision a person can achieve with glasses or contact lenses if needed.
  • ETDRS method: A standard way to measure vision in eye studies using a letter chart.

References